DRUG STUDY

Name: Casilao, Mike Arone H. Date: June 29, 2023

NURSING
MEDICATION CLASSIFICATION/ ACTION INDICATIONS CONTRAINDICATIONS SIDE EFFECTS ADVERSE EFFECTS
RESPONSIBILITIES

Generic Name: DRUG CLASS: Treatment This drug is contraindicated  GI disturbances  Lactic acidosis BEFORE:
PHARMACOTHERAPEUTIC: for gestational to patients with: such as diarrhea,  Increase in
Metformin Biguanide antihyperglycemic diabetes mellitus. nausea, vomiting, blood lactate
CLINICAL:  Hypersensitivity to abdominal bloating, levels  Verify doctor’s
Brand Name: Antidiabetic agent metformin flatulence, and  Decrease in order in regards
 Severe renal anorexia blood pH to the medication.
Fortamet, disease/dysfunction;  Unpleasant/metallic  Electrolyte  Observe the ten
Glucophage, DRUG ACTION: acute or chronic taste that resolves Disturbances (10) rights of
Glucophage XR, Decreases hepatic production metabolic acidosis  Unexplained medication
spontaneously
Glumetza, Glycon of glucose. Decreases Hyperventilation administration
during therapy
intestinal absorption of Use cautiously in:  Myalgia  Obtain a general
Usual glucose, improves insulin  Malaise medical history
Dosage/Frequency: sensitivity.  Hepatic impairment  Drowsiness from patient.
Therapeutic Effect:  Excessive  Cardiovascular  Obtain and record
500 mg twice-daily Improves glycemic control, acute/chronic collapse vital signs
or 850 mg once stabilizes/decreases body alcohol intake,  Acute HF  Assess for any
daily. elderly  Acute MI contraindications
weight, improves lipid profile.
 Recommend  Prerenal to the drug.
PHARMACOKINETICS:
Usual Route: temporary azotemia  Educate about
Slowly, incompletely
side effects
absorbed after PO discontinuation at
Oral of drug.
administration. Food delays, time of or before
decreases extent of iodinated contrast DURING:
absorption. Protein binding: imaging procedures  Prepare a cup of
Drug Order:
Negligible. Primarily in pts with CrCl of water at bed side
 distributed to intestinal 30-60 mL/min of the patient
Metformin 850 mg 1 mucosa, salivary glands.  History of hepatic  Instruct patient to
tab OD (12 PM) Primarily excreted unchanged disease and take full course
in urine. Removed by alcoholism prescribed and
hemodialysis. Half-life 9-17 offer water after.
hrs.  Stay with patient
throughout whole
Onset: Unknown duration of
Peak: Up to 2 wk administration.
Duration: 2 wk after drug
discontinued AFTER:
 Monitor the side
and adverse
effects.
 Discontinue drug
if hypersensitivity
reactions occur.
 Monitor fasting
serum glucose.
 Document the
time, location,
dose, and
medication given
to the client.
 Determine if
patient is taking
dose as
recommended.
 Observe and
report any side
effects.